These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2154757)

  • 1. Mechanisms of hormone and cytotoxic drug interactions in the development and treatment of breast cancer.
    Clarke R; Lippman ME; Dickson RB
    Prog Clin Biol Res; 1990; 322():243-78. PubMed ID: 2154757
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of breast cancer.
    Cohen IA; Keller JH; Abate MA
    Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of hematopoietic growth factors to support cytotoxic chemotherapy for patients with breast cancer.
    Demetri GD
    Hematol Oncol Clin North Am; 1994 Feb; 8(1):233-49. PubMed ID: 8150782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
    Tan M; Li P; Sun M; Yin G; Yu D
    Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):1-4. PubMed ID: 10203263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
    Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for breast cancer. Part 2: Treatment of metastatic breast cancer.
    Hill GJ
    W V Med J; 1986 Aug; 82(8):267-9. PubMed ID: 3463009
    [No Abstract]   [Full Text] [Related]  

  • 8. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
    Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hormones, growth factors and their receptors during differentiation and dedifferentiation--paraneoplastic hormone secretion in malignant tumors. Report of the 32nd Symposium of the German Society of Endocrinology].
    Dietel M; Müller OA
    Dtsch Med Wochenschr; 1988 Sep; 113(39):1528-33. PubMed ID: 2844493
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of endocrine therapy.
    Pritchard KI; Sutherland DJ
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):765-805. PubMed ID: 2481670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts.
    Paulus P; Stanley ER; Schäfer R; Abraham D; Aharinejad S
    Cancer Res; 2006 Apr; 66(8):4349-56. PubMed ID: 16618760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of signal transduction by hormones and growth factors. Proceedings of the Second International Symposium on Cellular Endocrinology. Lake Placid, New York, September 8-11, 1986.
    Prog Clin Biol Res; 1987; 249():1-321. PubMed ID: 2823287
    [No Abstract]   [Full Text] [Related]  

  • 13. Direct antiproliferative effect of triptorelin on human breast cancer cells.
    Marini L; Iacopino F; Schinzari G; Robustelli della Cuna FS; Mantovani G; Sica G
    Anticancer Res; 1994; 14(5A):1881-5. PubMed ID: 7847821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.
    Pusztai L; Esteva FJ; Cristofanilli M; Hung MC; Hortobagyi GN
    Cancer Treat Rev; 1999 Oct; 25(5):271-7. PubMed ID: 10544071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of the new biology for therapy in breast cancer.
    Sledge GW
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):76-81. PubMed ID: 8614850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen, uridine transport, and dome formation in human breast cancer cells.
    Allegra CJ
    Cancer J Sci Am; 1995; 1(3):182-3. PubMed ID: 9166472
    [No Abstract]   [Full Text] [Related]  

  • 18. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy.
    Fryar EB; Das JR; Davis JH; Desoto JA; Laniyan I; Southerland WM; Bowen D
    Anticancer Res; 2006; 26(3A):1861-7. PubMed ID: 16827118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the toxicity of chemotherapy for breast cancer--the need for vigilance.
    Erban JK; Lau J
    J Natl Cancer Inst; 2006 Aug; 98(16):1096-7. PubMed ID: 16912256
    [No Abstract]   [Full Text] [Related]  

  • 20. Biology of residual breast cancer after therapy: a kinetic interpretation.
    Norton L
    Prog Clin Biol Res; 1990; 354A():109-32. PubMed ID: 2247484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.